Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00206167
NCT00206167CompletedPhase 3

A 12-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid Compared to Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

AstraZeneca216 sites in 1 country1,600 target enrollmentStarted: April 1, 2005Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
1,600
Locations
216
Primary Endpoint
Pre-dose and 1-hour post-dose FEV1 over the 12 months treatment period
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to compare Symbicort in a pressurized metered-dose inhaler (pMDI) with formoterol and placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
40 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •A clinical diagnosis of COPD with symptoms for more than 2 years.
  • •Smoking history of 10 or more pack years
  • •A history of at least one COPD exacerbation requiring a course of oral steroids and/or antibiotics within 1-12 months before first visit.

Exclusion Criteria

  • •A history of asthma
  • •Patients taking oral steroids
  • •Any significant disease or disorder that may jeopardize the safety of the patient

Outcomes

Primary Outcomes

Pre-dose and 1-hour post-dose FEV1 over the 12 months treatment period

Secondary Outcomes

  • Patient-reported outcome variables regarding disease status (incl. PEF), collected via questionnaires and diaries
  • Health care utilization
  • Safety variables, including adverse events, vital signs, ECG, physical examination, hematology, and clinical chemistry.
  • all variables assessed over the 12 months treatment period

Investigators

Sponsor Class
Industry

Study Sites (216)

Loading locations...

Similar Trials

Completed
Phase 3
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a DayAsthma
NCT01360021AstraZeneca214
Completed
Phase 3
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPDChronic Obstructive Pulmonary Disease
NCT00419744AstraZeneca1,200
Completed
Phase 3
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and AdolescentsAsthma
NCT01444430AstraZeneca12,460
Completed
Phase 3
DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in AdultsAsthma
NCT00252863AstraZeneca1,600
Completed
Phase 3
SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and AdultsAsthma
NCT00259792AstraZeneca1,000